Clinical trials Below are current clinical trials.294 studies in Oncology (Medical) (open studies only). Filter this list of studies by location, status and more. A Study To Evaluate Regulation Of The Metabolism Of T-Cells By The Tumor Microenvironment In Ovarian Cancer Metastasis Scottsdale/Phoenix, Ariz. The purpose of this study is to analyze how the immune cell repertoire changes during early and late metastasis which could shed light into how the tumor microenvironment in metastatic disease becomes tumor permissive. A Study To Evaluate Advanced Development Of Desorption Electrospray Ionization Mass Spectrometry For Intraoperative Molecular Diagnosis Of Brain Cancer Jacksonville, Fla. The purpose of this study is to explore the translational abilities of desorption electrospray ionization mass spectrometry (DESI-MS) as intraoperative diagnostic tool to identify cancerous versus noncancerous tissue and estimate the percentage of tumor infiltration in tissue biopsies, by monitoring depletion of N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring the 2-hydroxyglutarate (2HG) and, therefore, differentiate between IDH-mutant and wild-type gliomas. A Study To Evaluate Immune-related Biomarkers For Pathological Response In Stage II-III HER2-positive Breast Cancer Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate invasive disease-free survival (iDFS) of multi-epitope HER2 vaccine vs. placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant chemotherapy, and to evaluate the safety of multi-epitope HER2 vaccine given concurrently with T-DM1 maintenance therapy. Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel Rochester, Minn., Jacksonville, Fla. The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release. Testing The Addition Of An Anti-cancer Drug, Selinexor, To The Usual Chemotherapy Treatment (Temozolomide) For Brain Tumors That Have Returned After Previous Treatment Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of phase 1 of this trial is to determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as determined by dose-limiting toxicities [DLTs] and the total toxicity profile. The purpose of phase 2 of this trial is to evaluate the effectiveness of sequentially administering temozolomide and selinexor in recurrent glioblastoma as determined by progression-free survival [PFS]. Testing The Use Of Chemotherapy After Surgery For High-Risk Pancreatic Neuroendocrine Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Human Saliva as a Non-Invasive Tool for Cancer Diagnostics Using Surface-Enhanced Raman Spectroscopy Eau Claire, Wis. The purpose of this study is to develop a rapid, reliable, inexpensive, and non-invasive method for cancer detection and screening. To use Surface-Enhanced Raman Spectroscopy (SERS), a powerful analytical technique that provides detailed and specific information at a molecular level, to detect cancer biomarkers in a patient’s saliva. Optical Fusion Trans-Perineal Grid Rochester, Minn. The purpose of this study is to evaluate and assess a new perineal access tool to enable image guided prostate interventions by Clear Guide Medical in collaboration with the Mayo Clinic. Database of All Patients with Peritoneal Surface Malignancies Treated at Mayo Clinic Rochester, Minn. The purpose of this study is to: Establish a prospective database of all patients with peritoneal surface malignancies seen by Dr. Travis Grotz at the Mayo Clinic, Rochester. Design and implement quality improvement projects utilizing this database Design and implement outcomes research using this prospective database Design and implement quality of life studies using this prospective database Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to determine freedom from ipsilateral breast recurrence occurrences in patients receiving partial breast proton radiation therapy limited to the region of the tumor at 3 years. Pagination Clinical studies PrevPrevious Page Go to page 88 Go to page 99 Go to page 1010 Go to page 1111 Go to page 1212 NextNext Page Request an appointment Expertise & rankingsResearch Dec. 24, 2024 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, have been recognized among the top Cancer hospitals in the nation by U.S. News & World Report. Learn more about this top honor Oncology (Medical)DepartmenthomeSectionsOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20180179 Medical Departments & Centers Oncology (Medical)